Replay available

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call

Lantern Pharma Inc. (NASDAQ: LTRN) Q3 2024 earnings conference call, held 2024-11-07. Replay captured from the company's public earnings webcast.

Thu, November 7, 2024 at 4:30 PMendedReplay
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call

Hosted by

Featured presenters

Pana Sharma

President and CEO of Lantern Pharma

David Margrave

Chief Financial Officer of Lantern Pharma

Dr. Kishore Bhatia

Chief Scientific Officer of Lantern Pharma

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Lantern Pharma Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.149 -- 00:00:03.673 Good afternoon and welcome to our third quarter 2024 00:00:03.673 -- 00:00:08.758 earnings call. As a reminder, this call is being recorded and all attendees are in 00:00:08.758 -- 00:00:13.823 a listen-only mode. We will open the call for questions and answers after our management's 00:00:13.823 -- 00:00:18.888 presentation. A webcast replay of today's conference call will be available on 00:00:18.888 -- 00:00:21.731 our website at lanternpharma.com 00:00:21.731 -- 00:00:27.025 shortly after the call. We issued a press release after market closed today summarizing 00:00:27.025 -- 00:00:31.918 our financial results and progress across the company for the third quarter ended September 00:00:31.918 -- 00:00:33.918 30, 2024. 00:00:34.930 -- 00:00:39.693 A copy of this release is available through our website at lanternpharma.com, 00:00:39.693 -- 00:00:43.916 where you will also find a link to the slides management we'll be referencing on today's 00:00:43.916 -- 00:00:49.219 call. We would like to remind everyone that remarks about future expectations, 00:00:49.219 -- 00:00:54.301 performance, estimates, and prospects constitute forward-looking statements 00:00:54.301 -- 00:00:59.082 for purposes of safe harbor provisions under the private securities litigation reform 00:00:59.082 -- 00:01:01.563 act of 1995. 00:01:01.563 -- 00:01:06.325 Lantern Pharma cautions that these forward-looking statements are subject to risks and 00:01:06.325 -- 00:01:12.458 uncertainties that may cause actual results to differ materially from those anticipated. 00:01:12.458 -- 00:01:17.266 A number of factors could cause actual results to differ materially from those indicated 00:01:17.266 -- 00:01:22.174 by forward-looking statements, including results of c...